PHCU.F Stock Overview Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Photocure ASA Competitors Price History & Performance
Summary of share price highs, lows and changes for Photocure Historical stock prices Current Share Price NOK 5.60 52 Week High NOK 6.50 52 Week Low NOK 4.47 Beta 0.92 1 Month Change 25.00% 3 Month Change n/a 1 Year Change -8.20% 3 Year Change n/a 5 Year Change -42.86% Change since IPO -41.05%
Recent News & Updates
Photocure ASA, Annual General Meeting, May 05, 2025 Dec 13 Photocure ASA to Report Fiscal Year 2024 Results on Apr 11, 2025
Photocure ASA Announces Board Appointments May 25 Photocure ASA Reiterates Financial Guidance for the Year 2024 May 16
Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence Apr 30
Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy Mar 29 See more updates
Photocure ASA, Annual General Meeting, May 05, 2025 Dec 13 Photocure ASA to Report Fiscal Year 2024 Results on Apr 11, 2025
Photocure ASA Announces Board Appointments May 25 Photocure ASA Reiterates Financial Guidance for the Year 2024 May 16
Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence Apr 30
Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy Mar 29 Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024
Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China Nov 29
Photocure ASA Announces Change of Board Composition Sep 28
Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint Aug 12
Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China Jul 07
Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC Feb 20
Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week Jan 05
Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week Jan 04 Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023
Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy Dec 05
Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc Oct 06 PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S Sep 28
Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology Sep 20
Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy Sep 08
Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development Sep 01
Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States Jul 28
Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki Jun 13
Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022. Jun 04
Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand Mar 06
Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model Feb 28
Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S Feb 07
Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology Jun 25
Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira) Jun 22
Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020. Mar 28
Photocure ASA Suspends Guidance for 2023 Mar 04 Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021
Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan Jan 28
Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan Jan 26
Photocure Announces New Cevira Patent In Europe Oct 06
Photocure Launches European Hexvix Operations Oct 03
Photocure ASA Provides Revenue Guidance for the Year 2020 Aug 19 Shareholder Returns PHCU.F US Pharmaceuticals US Market 7D 0% -0.6% -0.2% 1Y -8.2% 3.0% 25.6%
See full shareholder returns
Return vs Market: PHCU.F underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is PHCU.F's price volatile compared to industry and market? PHCU.F volatility PHCU.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.1%
Stable Share Price: PHCU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PHCU.F's volatility change over the past year.
About the Company Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
Show more Photocure ASA Fundamentals Summary How do Photocure's earnings and revenue compare to its market cap? PHCU.F fundamental statistics Market cap US$145.30m Earnings (TTM ) US$1.24m Revenue (TTM ) US$46.25m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PHCU.F income statement (TTM ) Revenue NOK 526.25m Cost of Revenue NOK 29.11m Gross Profit NOK 497.15m Other Expenses NOK 482.98m Earnings NOK 14.16m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
Earnings per share (EPS) 0.52 Gross Margin 94.47% Net Profit Margin 2.69% Debt/Equity Ratio 0%
How did PHCU.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 06:47 End of Day Share Price 2024/12/26 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Photocure ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hans Bohn Beringer Finance AB null null Brookline Capital Markets Patrik Ling DNB Markets
Show 2 more analysts 
